GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Cyclically Adjusted FCF per Share

NovoCure (STU:038) Cyclically Adjusted FCF per Share : €-0.37 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NovoCure Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

NovoCure's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.372. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.37 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-11), NovoCure's current stock price is €20.07. NovoCure's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-0.37. NovoCure's Cyclically Adjusted Price-to-FCF of today is .


NovoCure Cyclically Adjusted FCF per Share Historical Data

The historical data trend for NovoCure's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Cyclically Adjusted FCF per Share Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.37

NovoCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.37 -0.37

Competitive Comparison of NovoCure's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted Price-to-FCF falls into.



NovoCure Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovoCure's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.372/131.7762*131.7762
=-0.372

Current CPI (Mar. 2024) = 131.7762.

NovoCure Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -0.386 99.621 -0.511
201506 -0.282 100.684 -0.369
201509 -0.266 100.392 -0.349
201512 -0.320 99.792 -0.423
201603 -0.360 100.470 -0.472
201606 -0.376 101.688 -0.487
201609 -0.398 101.861 -0.515
201612 -0.187 101.863 -0.242
201703 -0.314 102.862 -0.402
201706 -0.072 103.349 -0.092
201709 0.007 104.136 0.009
201712 -0.046 104.011 -0.058
201803 -0.171 105.290 -0.214
201806 -0.084 106.317 -0.104
201809 0.040 106.507 0.049
201812 0.142 105.998 0.177
201903 -0.062 107.251 -0.076
201906 0.061 108.070 0.074
201909 0.103 108.329 0.125
201912 0.035 108.420 0.043
202003 -0.010 108.902 -0.012
202006 0.078 108.767 0.095
202009 0.220 109.815 0.264
202012 0.353 109.897 0.423
202103 0.113 111.754 0.133
202106 0.189 114.631 0.217
202109 0.173 115.734 0.197
202112 0.001 117.630 0.001
202203 -0.077 121.301 -0.084
202206 0.105 125.017 0.111
202209 0.161 125.227 0.169
202212 -0.091 125.222 -0.096
202303 -0.202 127.348 -0.209
202306 -0.258 128.729 -0.264
202309 -0.233 129.860 -0.236
202312 -0.183 129.419 -0.186
202403 -0.372 131.776 -0.372

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


NovoCure  (STU:038) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


NovoCure Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (STU:038) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines